NQO2Quinone Oxidoreductase 2 (human gene)
References in periodicals archive ?
Protherics said its NQO2 treatment is anticipated to be relatively selective for tumour tissue, potentially making it more effective and safer compared to other chemotherapy agents.
NQO2 activates a compound - known as an antitumour prodrug - which has a direct toxic effect on cells, preventing their reproduction or growth.
Andrew Heath, chief executive of Protherics, said: 'Activation of the prodrug in man is a key step towards achieving NQO2's potential to selectively target a number of tumour types